Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
The recommendation has been sent to the DCGI for approval
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Pfizer and Moderna are also working on vaccines that target the Omicron variant
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
It would be the first protein-based alternative available in Israel
Subscribe To Our Newsletter & Stay Updated
